



Subharmonic scattering of ultrasound contrast agent microbubbles may be an effective and promising tool for portal vein pressure estimation

Mingchang Pang, Huayu Yang

Department of Liver Surgery, Peking Union Medical College Hospital (PUMCH), Peking Union Medical College (PUMC) & Chinese Academy of Medical Sciences (CAMS), Beijing, China

Correspondence to: Huayu Yang, PhD. Department of Liver Surgery, Peking Union Medical College Hospital (PUMCH), Peking Union Medical College (PUMC) & Chinese Academy of Medical Sciences (CAMS), No. 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China. Email: dolphinyahy@hotmail.com.

Keywords: Subharmonic scattering; ultrasound contrast agent; portal vein pressure (PVP); non-invasive estimation

Submitted Jul 01, 2023. Accepted for publication Jul 11, 2023. Published online Jul 17, 2023.

doi: 10.21037/hbsn-23-336

View this article at: <https://dx.doi.org/10.21037/hbsn-23-336>

Portal hypertension (PH) is a commonly observed syndrome in patients with cirrhosis and other chronic liver diseases (1). It is closely associated with severe clinical complications, including upper gastrointestinal hemorrhage, ascites, hepatic encephalopathy, and liver failure (2-6). Portal vein pressure (PVP) is a prognostic indicator for patients with cirrhosis, and PH is a contraindication for hepatectomy (7,8). Currently, the gold standard for assessing PVP is the measurement of PVP gradient [hepatic venous pressure gradient (HVPG)], which is indirectly determined by placing a catheter in the hepatic vein (3). However, the invasive nature of this procedure and the associated risks of bleeding, bile leakage, and infection restrict its clinical applicability (9,10). Hence, there is an urgent need to develop a non-invasive method for accurately measuring PVP, catering to the demand for close clinical monitoring of PVP.

In recent years, advancements in ultrasound contrast agent microbubbles and imaging technology have opened up possibilities for non-invasive hemodynamic monitoring. Ultrasonic contrast agent microbubbles are composed of a gas core surrounded by a lipid or polymer shell. These microbubbles exhibit changes in size and acoustic properties in response to ambient pressure variations, owing to its compressibility (11). Leveraging this characteristic, a novel technology known as subharmonic-aided pressure estimation (SHAPE) has emerged, which utilizes ultrasound contrast agents (such as SonoVue and Sonazoid) as

pressure sensors. SHAPE relies on the correlation between microbubble subharmonics and ambient pressure, enabling non-invasive assessment of blood pressure (12). This innovative technology has garnered significant attention and is currently undergoing in-depth research. In a study conducted by Eisenbrey *et al.* (13), the SHAPE gradient between the portal vein and hepatic vein was compared with HVPG measurement. The findings indicated a generally good agreement between the two, suggesting that the SHAPE technique holds potential as a valuable tool for diagnosing clinical PH. Another clinical study involving 125 patients, which measured PVP using Sonazoid microbubbles, revealed consistent results between the SHAPE gradient and HVPG measurements (14). This suggests that SHAPE could be a promising technique for non-invasive detection of PH.

In recent years, there has been significant advancement in the estimation of PVP using the SHAPE technique. Xu *et al.* (15) conducted *in vitro* simulation experiments utilizing two confocal single element transducers. The results revealed that the subharmonic scattering of SonoVue microbubbles exhibited three stages: the first growth stage (40–300 kPa), saturation (300–400 kPa), and the second growth stage (400–540 kPa). The second growth stage was found to be more suitable for measuring lower ambient pressures. At a high incident acoustic pressure of 520 kPa, there was a strong correlation between subharmonic amplitude and ambient pressure. Lu *et al.* (16) established

a PH model using two dogs and demonstrated a linear correlation between subharmonic amplitude and PVP (<20 mmHg) at an incident acoustic pressure of 453 kPa. *In vivo* experiments conducted by Xu *et al.* using canine models of PH further validated these findings. They reported high sensitivity, specificity, and accuracy rates of 93.3%, 91.7%, and 92.6%, respectively, in diagnosing PH when the incident acoustic pressure was set at 563 kPa (17). These experimental findings indicate that the subharmonic scattering of ultrasonic contrast agent microbubbles offers a promising non-invasive method for assessing PVP.

While the existing *in vitro* simulation experiments and animal studies have yielded promising outcomes, addressing the challenges posed by attenuation through various human tissues and the heterogeneity among clinical patients remains an urgent concern. Furthermore, optimizing experimental parameters to enhance the sensitivity and accuracy of SHAPE technology in estimating PVP represents a significant current challenge. Additionally, large-scale clinical studies are necessary to validate the feasibility and clinical value of utilizing SonoVue microbubbles as non-invasive sensors for PVP estimation.

Acknowledgments

Funding: This work was supported by the National Natural Science Foundation of China (No. 32271470), National High Level Hospital Clinical Research Funding (No. 2022-PUMCH-B-034), Beijing Natural Science Foundation (No. 7212077), and CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2021-I2M-1-058).

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, *Hepatobiliary Surgery and Nutrition*. The article did not undergo external peer review.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at <https://hbsn.amegroups.com/article/view/10.21037/hbsn-23-336/coif>). HY serves as an unpaid editorial board member of *Hepatobiliary Surgery and Nutrition*. The other author has no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are

appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Belli A, Cioffi L, Russo G, et al. Liver resection for hepatocellular carcinoma in patients with portal hypertension: the role of laparoscopy. *Hepatobiliary Surg Nutr* 2015;4:417-21.
2. Ridola L, Gioia S, Faccioli J, et al. Determinants of prognosis in cirrhosis: a new outlook. *Hepatobiliary Surg Nutr* 2022;11:759-61.
3. Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. *Hepatology* 2017;65:310-35.
4. Ashkenazi E, Kovalev Y, Zuckerman E. Evaluation and treatment of esophageal varices in the cirrhotic patient. *Isr Med Assoc J* 2013;15:109-15.
5. Zhang M, Ma J, An Y, et al. Construction of an intrahepatic portosystemic shunt using the magnetic compression technique: preliminary experiments in a canine model. *Hepatobiliary Surg Nutr* 2022;11:611-5.
6. Rassam F, Olthof PB, Takkenberg B, et al. Functional assessment of liver regeneration after major hepatectomy. *Hepatobiliary Surg Nutr* 2022;11:530-8.
7. Ferrer-Fàbrega J, Bruix J. Resection vs. transplantation for hepatocellular carcinoma: a never ending challenge. *Hepatobiliary Surg Nutr* 2023;12:443-6.
8. Berzigotti A, Reig M, Abraldes JG, et al. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. *Hepatology* 2015;61:526-36.
9. Bosch J, Abraldes JG, Berzigotti A, et al. The clinical use of HVPG measurements in chronic liver disease. *Nat Rev Gastroenterol Hepatol* 2009;6:573-82.
10. Suk KT. Hepatic venous pressure gradient: clinical use in chronic liver disease. *Clin Mol Hepatol* 2014;20:6-14.

11. Calliada F, Campani R, Bottinelli O, et al. Ultrasound contrast agents: basic principles. *Eur J Radiol* 1998;27 Suppl 2:S157-60.
12. Dave JK, Halldorsdottir VG, Eisenbrey JR, et al. Investigating the efficacy of subharmonic aided pressure estimation for portal vein pressures and portal hypertension monitoring. *Ultrasound Med Biol* 2012;38:1784-98.
13. Eisenbrey JR, Dave JK, Halldorsdottir VG, et al. Chronic liver disease: noninvasive subharmonic aided pressure estimation of hepatic venous pressure gradient. *Radiology* 2013;268:581-8.
14. Gupta I, Eisenbrey JR, Machado P, et al. Diagnosing Portal Hypertension with Noninvasive Subharmonic Pressure Estimates from a US Contrast Agent. *Radiology* 2021;298:104-11.
15. Xu G, Lu H, Yang H, et al. Subharmonic Scattering of SonoVue Microbubbles Within 10-40-mmHg Overpressures In Vitro. *IEEE Trans Ultrason Ferroelectr Freq Control* 2021;68:3583-91.
16. Lu H, Xu G, Wang Y, et al. Correlation Between Portal Vein Pressure and Subharmonic Scattering Signals From SonoVue Microbubbles in Canines. *Ultrasound Med Biol* 2023;49:203-11.
17. Xu G, Wang Y, Lu H, et al. Portal vein pressure estimation and portal hypertension discrimination based on subharmonic scattering of ultrasound contrast agent microbubbles. *IEEE Trans Biomed Eng* 2023. [Epub ahead of print]. doi: 10.1109/TBME.2023.3293952.

Cite this article as: Pang M, Yang H. Subharmonic scattering of ultrasound contrast agent microbubbles may be an effective and promising tool for portal vein pressure estimation. *HepatoBiliary Surg Nutr* 2023;12(4):625-627. doi: 10.21037/hbsn-23-336